Assessing treatment pattern and cost consequence of lopinavir/ritonavir versus nelfinavir therapy in HIV patients

被引：0
|
作者：
Luo, MP [1 ]
Boggs, R [1 ]
Bernstein, B [1 ]
Sun, E [1 ]
Ashraf, T [1 ]
机构：
[1] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ANTIVIRAL THERAPY | 2002年 / 7卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
117
引用
收藏
页码：L75 / L76
页数：2
相关论文
共 50 条
  • [21] Risk factors for body fat composition changes in patients treated with lopinavir/ritonavir or nelfinavir
    da Silva, B
    King, M
    Cernohous, P
    Kelly, C
    Tressler, R
    Brun, S
    ANTIVIRAL THERAPY, 2003, 8 (04) : L68 - L68
  • [22] The Effect of Acid Reduction With a Proton Pump Inhibitor on the Pharmacokinetics of Lopinavir or Ritonavir in HIV-Infected Patients on Lopinavir/Ritonavir-Based Therapy
    Overton, Edgar T.
    Tschampa, Jean M.
    Klebert, Michael
    Royal, Mike
    Rodriguez, Mark
    Spitz, Teresa
    Kim, GeYoul
    Mondy, Kristin E.
    Acosta, Edward P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1050 - 1055
  • [23] Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children
    Rudin, Christoph
    Burri, Marcus
    Shen, Yang
    Rode, Richard
    Nadal, David
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (05) : 431 - 437
  • [24] Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naive patients with HIV-1 infection
    Calza, L.
    Manfredi, R.
    Pocaterra, D.
    Chiodo, F.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2008, 19 (08) : 541 - 544
  • [25] Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir plus Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World
    Foglia, Emanuela
    Bonfanti, Paolo
    Rizzardini, Giuliano
    Bonizzoni, Erminio
    Restelli, Umberto
    Ricci, Elena
    Porazzi, Emanuele
    Scolari, Francesca
    Croce, Davide
    PLOS ONE, 2013, 8 (02):
  • [26] Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir
    Václavíková, J
    Machala, L
    Stanková, M
    Linka, M
    Brucková, M
    Vandasová, J
    Konvalinka, J
    JOURNAL OF CLINICAL VIROLOGY, 2005, 33 (04) : 319 - 323
  • [27] Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir
    Guest, JL
    Ruffin, C
    Tschampa, JM
    DeSilva, KE
    Rimland, D
    PHARMACOTHERAPY, 2004, 24 (06): : 727 - 735
  • [28] Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil
    Tenore, Simone
    Ferreira, Paulo A.
    Diaz, Ricardo Sobhie
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (04) : 526 - 528
  • [29] Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
    Zhu, Li
    Liao, Shanmei
    Child, Michael
    Zhang, Jenny
    Persson, Anna
    Sevinsky, Heather
    Eley, Timothy
    Xu, Xiaohui
    Krystal, Mark
    Farajallah, Awny
    McGrath, Donnie
    Molina, Jean-Michel
    Bertz, Richard
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (02) : 465 - 468
  • [30] Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment
    Barragan, Patricia
    Podzamczer, Daniel
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (13) : 2363 - 2375
12345